BTX:NYE-Brooklyn ImmunoTherapeutics, Inc (USD)

COMMON STOCK | Other | NYE

Last Closing Price

USD 43.09

Change

-12.10 (-21.92)%

Market Cap

USD 2.73B

Volume

6.90M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company is based in Brooklyn, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-05 )

Largest Industry Peers for Other

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
BMS Bemis Company, Inc

N/A

USD370,676,430.93B 1,000,000.00 N/A
NAO Nordic American Offshore Ltd

N/A

USD387,070.41B N/A N/A
ITC ITC Holdings Corp

N/A

USD3,166.52B 22.84 N/A
MSF Morgan Stanley Emerging Market..

N/A

USD1,000.65B 24.60 N/A
HSBC-PA HSBC Holdings plc ADR A 1/40PF..

N/A

USD513.94B 53.22 N/A
SAN-PB Banco Santander, S.A. GTD PFD ..

N/A

USD384.67B 54.97 N/A
BAC-PW Bank of America Corporation

N/A

USD267.69B 9.46 N/A
BAC-PY Bank of America Corporation

N/A

USD263.53B 9.36 N/A
BEL Belmond Ltd

N/A

USD261.58B 15.94 N/A
TBB AT&T Inc. 5.35% GLB NTS 66

-0.17 (-0.64%)

USD163.10B 5.19 N/A

ETFs Containing BTX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Other)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4,124.51% 100% A+ 100% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 4,124.51% 100% A+ 100% A+
Trailing 12 Months  
Capital Gain 4,124.51% 99% A+ 100% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 4,124.51% 99% A+ 100% A+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 49.27% 94% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 49.27% 94% A 95% A
Risk Return Profile  
Volatility (Standard Deviation) 326.16% 6% F 2% F
Risk Adjusted Return 15.11% 28% F 32% F
Market Capitalization 2.73B 54% F 64% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Other)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 2.32 91% A- 97% A+
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -702.11 99% A+ 99% A+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -14,919.19% 6% F 1% F
Return on Invested Capital -194.90% 1% F 1% F
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio 62.51% 61% D- 55% F
Technical Ratios  
Short Ratio 0.14 87% B+ 92% A-
Short Percent N/A N/A N/A N/A N/A
Beta 3.15 1% F 3% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector